Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration?

Eye

Volumn 20, Issue 1, 2006, Pages 43-45

  Sivaprasad, Senswathi ^a   Saleh, G M ^a   Jackson, H ^a  

^a Princess Royal University Hospital   (United Kingdom)

Author keywords

Age related macular degeneration; Lesion size; Photodynamic therapy

Indexed keywords

AGED; ARTICLE; CLINICAL ARTICLE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MALE; PHOTODYNAMIC THERAPY; PROGNOSIS; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 30744479484     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6701787     Document Type: Article

References (6)

1. Lee P, Wang CC, Adamis AP. Ocular neovascularization: An epidemiologic review. Surv Ophthalmol 1998; 43: 245-269.
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol 1999; 117: 1329-1345.
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: Additional information regarding baseline lesion composition's impact on vision outcomes - TAP report No. 3. Arch Ophthalmol 2002; 120: 1443-1454.
4. Olsen TW, Feng X, Kasper TJ, Rath PF, Steuer ER. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 2004; 111(2): 250-255.
5. Axer-Siegel R, Ehrlich R, Yassur Y, Rosenblatt I, Kramer M, Priel E et al. Photodynamic therapy for age-related macular degeneration in a clinical setting: Visual results and angiographic patterns. Am J Ophthalmol 2004; 137(2): 258-264.
6. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age- related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001; 131: 541-560.